Mitoxantrone plus a corticosteroid is an established palliative treatment for men with metastatic, hormone-refractory prostate cancer. A recent international study has compared this approach with two docetaxel regimens, in an attempt to improve survival in these patients....
3844 Recent clinical trials have shown that the anti-tubule drug docetaxel (DTX, Taxotere®) increases the median survival of patients with hormone refractory prostate cancer (HRPC). An existing paradigm is that DTX exerts its antitumor activity by inducing apoptosis. This is based primarily on ...
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer Docetaxel is standard of care for androgen-independent prostate cancer (AIPC). Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in ...
Androgen receptor (AR) signalling drives neoplastic growth and therapy resistance in prostate cancer. Recent clinical data show that docetaxel combined with androgen deprivation therapy improves outcome in hormone-sensitive disease. We studied whether testosterone and AR signalling interferes with docetaxel ...
evidence-based content and advanced ai-enabled digital technologies. we have supported the work of our research and healthcare communities for more than 140 years. our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians...
Before iv glucocorticoid administration, patients should be screened for recent hepatitis, liver dysfunction, cardiovascular morbidity, severe hypertension, inadequately managed diabetes, and glaucoma. The cumulative dose should not exceed 8 g, and with the exception of sight-threatening GO the single dos...
Serrate C, Loriot Y, De La Motte Rouge T et al (2009) Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 20(5):965... C.,Serrate,Y.,... - 《Annals of Oncology Official ...
It is used to treat breast cancer, stomach cancer, prostate cancer, non-small-cell lung cancer, head and neck cancer [52]. View article Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy Hira Choudhury, ... Prashant Kesharwani, in International Journal of ...
The variability in response to conventional prostate cancer (PC) therapies, coupled with the emergent issue of drug resistance, underscores the critical need for innovative treatment strategies. Aerobic physical exercise reduced incidence of several canc
Most patients with prostate cancer inevitably progress to castration-resistant prostate cancer (CRPC), at which stage chemotherapeutics like docetaxel become the first-line treatment. However, chemotherapy resistance typically develops after an initial p